ReviewCirculation research2019
Device-Based Neuromodulation for Resistant Hypertension Therapy.
Review in Circulation research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Non-invasive Autonomic Neuromodulation Is Opening New Landscapes for Cardiovascular Diseases.Frontiers in physiology · 2020Pooled it
- The onset of hypertension in metabolic syndrome is independent of renal sympathetic innervation.Life science alliance · 2026Article
- Neuromodulation using Bioelectronics-enabled therapies to combat insulin resistance and its comorbidities.Journal of diabetes and metabolic disorders · 2026Review
- Central nervous system mechanisms of salt-sensitive hypertension.Physiological reviews · 2025Review
- Ultra-stretchable, adhesive and photothermal multifunctional hydrogel for renal denervation to treat hypertension.Materials today. Bio · 2025Article
- Resistant Hypertension: A Brief Review of Pathophysiology.Journal of general internal medicine · 2025Review
- Impaired inhibitory reno-renal reflex responses in chronic kidney disease.Frontiers in physiology · 2025Article
- Clinical trials in neuromodulatory treatment of drug-resistant hypertension and the need for spinal cord stimulation trials: a PRISMA systematic review.Bioelectronic medicine · 2024Review
- Advances on the Experimental Research in Resistant Hypertension.Current hypertension reports · 2024Review
- Carotid Baroreceptor Stimulation Ameliorates Pulmonary Arterial Remodeling in Rats With Hypoxia-Induced Pulmonary Hypertension.Journal of the American Heart Association · 2024Article
- Hypertension and Device-Based Therapies for Resistant Hypertension: An Up-to-Date Review.Cureus · 2024Review
- Efficacy and safety of 3D reconstruction and basket multi-electrode renal denervation (RDN) for refractory hypertensive patients with chronic kidney disease.Journal of clinical hypertension (Greenwich, Conn.) · 2024Article
- Device's design and clinical perspectives for resistant hypertension therapy.International journal of cardiology. Cardiovascular risk and prevention · 2024Review
- Brain Pathways in Blood Pressure Regulation.Hypertension (Dallas, Tex. : 1979) · 2024Article
- Mechanisms and treatment of obesity-related hypertension-Part 1: Mechanisms.Clinical kidney journal · 2024Review
- Soluble (Pro)Renin Receptor in Hypertension.Nephron · 2023Review
- Device-Based Therapy for Resistant Hypertension: An Up-to-Date Review.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2022Review
- Modeling the physiological roles of the heart and kidney in heart failure with preserved ejection fraction during baroreflex activation therapy.American journal of physiology. Heart and circulatory physiology · 2022Article
- Acute and Short-Term Autonomic and Hemodynamic Responses to Transcranial Direct Current Stimulation in Patients With Resistant Hypertension.Frontiers in cardiovascular medicine · 2022Article
- Skin Microhemodynamics and Mechanisms of Its Regulation in Type 2 Diabetes Mellitus.Biophysics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Despite availability of effective drugs for hypertension therapy, significant numbers of hypertensive patients fail to achieve recommended blood pressure levels on ≥3 antihypertensive drugs of different classes. These individuals have a high prevalence of adverse cardiovascular events and are defined as having resistant hypertension (RHT) although nonadherence to prescribed antihypertensive medications is common in patients with apparent RHT. Furthermore, apparent and true RHT often display increased sympathetic activity. Based on these findings, technology was developed to treat RHT by suppressing sympathetic activity with electrical stimulation of the carotid baroreflex and catheter-based renal denervation (RDN). Over the last 15 years, experimental and clinical studies have provided better understanding of the physiological mechanisms that account for blood pressure lowering with baroreflex activation and RDN and, in so doing, have provided insight into which patients in this heterogeneous hypertensive population are most likely to respond favorably to these device-based therapies. Experimental studies have also played a role in modifying device technology after early clinical trials failed to meet key endpoints for safety and efficacy. At the same time, these studies have exposed potential differences between baroreflex activation and RDN and common challenges that will likely impact antihypertensive treatment and clinical outcomes in patients with RHT. In this review, we emphasize physiological studies that provide mechanistic insights into blood pressure lowering with baroreflex activation and RDN in the context of progression of clinical studies, which are now at a critical point in determining their fate in RHT management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.